Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: a Non-inferiority, Open-label, Randomized-controlled Study

NCT03515096 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.

NCT NCT03515096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03515096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: a Non-inferiority, Open-label, Randomized-controlled Study
Lead sponsor
Shenzhen Second People's Hospital
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2018
Completion date
July 1, 2022
Enrollment
98 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eltrombopag, hematopoietic stem cell transplantation, thrombocytopenia